Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Paul Feig loves a plot twist. Why not reboot 'Die Hard' starring a woman? - 26 Top Computer game Control center
- 3Home Mechanization Frameworks for Brilliant Residing
- 4The beauty advent calendar boom is here. Sephora kids are all in.
- 5This Flashy Old-School Design Trend From Italy Still Has A Place In Modern Kitchens
- Brazil's agricultural research agency gets cannabis research greenlight
- Explosions heard across Tehran after IDF announces wave of strikes on regime terror targets
- CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation
- FDA proposes use of sunscreen ingredient popular in other countries
- Addiction-stricken community struggles to keep a syringe program going after Trump's order
- Instructions to Pick the Ideal SUV Size for Seniors
- Holiday destinations for Creature Sweethearts
- How to get tickets for AC/DC's 2026 'Power Up' Tour
- A Time of Careful Eating: Individual Tests in Nourishment
